By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


PAREXEL International 

Corporate Headquarters
195 West Street
Waltham  Massachusetts  02451  U.S.A.
Phone: 781-487-9900 Fax: 781-487-0525



At PAREXEL, the best minds in the industry are simplifying the journey from science to new treatments—and getting them into the hands of those who need them most. If you join us, you can be a part of that. Through innovative processes and technology, your journey with us will not only be challenging but truly rewarding. PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries.

Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.

PAREXEL Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates approximately 75 locations in over 50 countries around the world, and has more than 15,000 employees. For more information about PAREXEL International, visit

Key Statistics

Ownership: Public

Employees: 15,000 worldwide
Symbol: PRXL

Company News
PAREXEL (PRXL) Receives Shareholder Approval For Proposed Acquisition By Pamplona Capital Management 9/18/2017 8:21:35 AM
PAREXEL (PRXL) Launches Real-World Data Service Offering To Drive Value Demonstration Of New Treatments 9/6/2017 8:04:08 AM
PAREXEL (PRXL) Reports Fourth Quarter And Fiscal Year 2017 Results 8/29/2017 7:49:50 AM
PAREXEL (PRXL) Announces Date Of Fourth Quarter And Fiscal Year 2017 Earnings Release 8/22/2017 7:37:31 AM
PAREXEL (PRXL) And Osaka International Cancer Institute Form Alliance To Advance Clinical Research In Japan 8/21/2017 7:16:45 AM
PAREXEL (PRXL) Receives CEO Cancer Gold Standard Re-Accreditation 7/11/2017 8:10:26 AM
PAREXEL (PRXL) Sold to Investment Firm in $5 Billion Deal 6/20/2017 5:52:54 AM
PAREXEL (PRXL)’s Alberto Grignolo Named Fellow By DIA 6/19/2017 8:52:55 AM
PAREXEL (PRXL) Introduces Its Connected Journey™ Of Newly Integrated Data-Driven Services To Simplify Drug Development And Commercialization 6/19/2017 8:46:12 AM
PAREXEL (PRXL) Collaborates With Sanofi (SNY) To Advance The Use Of Wearable Devices In Life Science Industry 6/15/2017 8:06:02 AM